Quintiles-Invested Samsung Biologics Proceeds On Schedule
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's largest conglomerate Samsung Group announced April 22 the CEO and the company name of a joint venture with Quintiles Transnational Corp. making inroads into the biosimilar and biopharmaceutical business
You may also be interested in...
Quintiles Moves Fast In China With Dalian Center and Shanghai Lab As Local Studies Explode
After launching its local entity Kun Tuo in China, CRO Quintiles accelerated its pace in China with the opening of a center of excellence in Dalian and a partnership with Shanghai Clinical Research Center.
Quintiles Asia Strategic Planning Director Simranjit Singh On Korea’s Clinical Trial Strategy: An Interview With PharmAsia News
The CRO exec discusses Korea’s expanding role in global clinical trials and the rising interest among MNCs for conducting trials in Korea, as evidenced by Pfizer’s Xalkori.
Samsung Biologics Takes First Step In The CMO Business While Targeting Innovative Compounds By 2017
INCHEON, South Korea - Samsung Biologics entered the first stage of a plan to become a global biopharmaceutical company, breaking ground on a biologics manufacturing plant May 27. The company hopes to establish itself as a global contract manufacturer before entering the biosimilar sector with its first entrant, a biosimilar of the monoclonal antibody Rituxan (rituximab)